Literature DB >> 9148245

Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease.

C Schneider1, D Risser, L Kirchner, E Kitzmüller, N Cairns, H Prast, N Singewald, G Lubec.   

Abstract

In order to study whether Alzheimer-like neuropathological changes involve the central histaminergic system we measured the concentration of histamine, its precursor histidine as well as the activity of histidine decarboxylase (HDC) and histamine-N-methyl-transferase (HMT) in frontal cortex of aging Down syndrome (DS) patients, Alzheimer patients and control individuals. The study populations were also investigated for choline acetyltransferase (ChAT) activity, since reduced ChAT activity is an established biochemical hallmark in DS and Alzheimer disease (AD). HDC and ChAT activity were reduced in brains of both DS and Alzheimer patients versus control patients. Additionally, we observed a significant decrease of histamine levels in the DS group. Histamine levels in AD brains tended to be decreased. Histidine concentrations and HMT activities were comparable between the three groups. Thus, our results for the first time show histaminergic deficits in brains of patients with DS resembling the neurochemical pattern in AD. Neuropathological changes may be responsible for similar neurochemical alterations of the histaminergic system in both dementing disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148245     DOI: 10.1016/s0304-3940(97)13379-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  A voltammetric and mathematical analysis of histaminergic modulation of serotonin in the mouse hypothalamus.

Authors:  Srimal Samaranayake; Aya Abdalla; Rhiannon Robke; H Frederik Nijhout; Michael C Reed; Janet Best; Parastoo Hashemi
Journal:  J Neurochem       Date:  2016-06-27       Impact factor: 5.372

Review 2.  Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.

Authors:  Mera Alhusaini; Nermin Eissa; Ali K Saad; Rami Beiram; Bassem Sadek
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

3.  The histamine N-methyltransferase T105I polymorphism affects active site structure and dynamics.

Authors:  Karen Rutherford; W W Parson; Valerie Daggett
Journal:  Biochemistry       Date:  2007-12-23       Impact factor: 3.162

4.  Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome.

Authors:  Fabio M Simoes de Souza; Nicolas Busquet; Megan Blatner; Kenneth N Maclean; Diego Restrepo
Journal:  Sci Rep       Date:  2011-11-02       Impact factor: 4.379

Review 5.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

6.  VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome.

Authors:  Laura Del Hoyo; Laura Xicota; Klaus Langohr; Gonzalo Sánchez-Benavides; Susana de Sola; Aida Cuenca-Royo; Joan Rodriguez; Jose Rodríguez-Morató; Magí Farré; Mara Dierssen; Rafael de la Torre
Journal:  Front Behav Neurosci       Date:  2016-10-17       Impact factor: 3.558

7.  Ligand autoradiographical quantification of histamine H3 receptor in human dementia with Lewy bodies.

Authors:  Natasha L Lethbridge; Paul L Chazot
Journal:  Pharmacol Res       Date:  2016-08-31       Impact factor: 7.658

8.  The Usage of Histamine Type 1 Receptor Antagonist and Risk of Dementia in the Elderly: A Nationwide Cohort Study.

Authors:  Chuan-Chi Yang; Wu-Chien Chien; Chi-Hsiang Chung; Chung-Yu Lai; Nian-Sheng Tzeng
Journal:  Front Aging Neurosci       Date:  2022-03-18       Impact factor: 5.750

9.  Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome.

Authors:  Martina Kirstein; Alba Cambrils; Ana Segarra; Ana Melero; Emilio Varea
Journal:  Neurochem Res       Date:  2022-06-29       Impact factor: 4.414

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.